Summary
Merck & Co., Inc. reported its third-quarter 2010 financial results, highlighting continued revenue generation from key products despite the ongoing challenges and opportunities in the pharmaceutical industry. The company demonstrated solid operational performance, with a focus on managing expenses and investing in its product pipeline. Investors should pay close attention to the performance of Merck's established drugs and the progress of its late-stage pipeline candidates, which will be critical drivers of future growth.
Financial Highlights
52 data pointsBeta
Financial Statements
Beta
| Revenue | $11.12B |
| Cost of Revenue | $4.19B |
| Gross Profit | $6.93B |
| R&D Expenses | $2.32B |
| SG&A Expenses | $3.19B |
| Interest Expense | $173.00M |
| Net Income | $342.00M |
| EPS (Basic) | $0.11 |
| EPS (Diluted) | $0.11 |
| Shares Outstanding (Basic) | 3.08B |
| Shares Outstanding (Diluted) | 3.10B |
Key Highlights
- 1Revenue generation continues from key established pharmaceutical products, indicating sustained market demand.
- 2The company is actively managing its expense structure to support profitability and strategic investments.
- 3Progress in the product pipeline remains a critical focus, with potential implications for long-term revenue streams.
- 4The company is navigating the evolving regulatory and competitive landscape of the pharmaceutical sector.
- 5Cash flow from operations remains a key indicator of the company's financial health and ability to fund R&D and shareholder returns.